BioWorld

June 2, 2006

Cangene Gets $362M Contract Under BioShield For Botulism

The U.S. government has contracted with the Canadian firm Cangene Corp. on a $362 million agreement for a botulism treatment, the first award for that potential bioterror agent. (BioWorld Today) Read More

Proteolix Series B: $45M To Boost Proteasome Program

New Research Helps Explain Neurology Drug Mechanisms

Ambion Spin-Off Asuragen Brings In $49M Via Series A

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Flow Neuro wins FDA nod for at-home device for depression

BioWorld MedTech

Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...